Use of Pulmonary Arterial Hypertension–Specific Therapy in Overweight or Obese Patients with Obstructive Sleep Apnea and Pulmonary Hypertension

Abstract

Pulmonary hypertension (PH) in overweight or obese patients with obstructive sleep apnea (OSA) may be multifactorial. The effect of pulmonary artery hypertension (PAH)-specific drugs on PH and exercise capacity in such patients is unknown. We performed a retrospective review of overweight or obese patients with OSA and PH who were treated with PAH-specific therapy in our PH clinic. We identified 9 female and 2 male patients. The mean age AE SD was 54.9 AE 9.3 years. The mean pulmonary artery pressure at the time of diagnosis of PH was 39.8 AE 16.1 mmHg. The right atrial pressure was 11.1 AE 4.5 mmHg, the pulmonary artery wedge pressure was 14.1 AE 2.9 mmHg, the cardiac index was 2.6 AE 0.5 L/min/m 2 , and the pulmonary vascular resistance index was 10.6 AE 7.1 Wood units/m 2 . The indications for use of PAHspecific therapy were dyspnea in association with right heart failure (n ¼ 4), persistent PH despite compliance with nocturnal positive airway pressure (PAP) therapy (n ¼ 4), or inability to tolerate PAP therapy (n ¼ 3). PH was treated with an endothelin receptor antagonist (n ¼ 8) or a phosphodiesterase-5 inhibitor (n ¼ 3). The 6-minute walk distance (6MWD) improved significantly, from 234 AE 49.7 to 258 AE 54.6 m (24 m [95% confidence interval (CI): 6.5-341.5 m]; P ¼ 0.014) over a period of 4.4 AE 1.8 months (n ¼ 8) and from 241.7 AE 48.5 to 289.9 AE 91 m (48 m [95% CI: 5.5-90.8 m]; P ¼ 0.033) in those with a longer follow-up period of 12.1 AE 6.4 months (n ¼ 7). The systolic pulmonary artery pressure dropped significantly, from 64 AE 25.2 to 42 AE 10.4 mmHg (22 mmHg [95% CI: 4 -40 mmHg]; P ¼ 0.024) over a period of 6.1 AE 4.1 months (n ¼ 7). In conclusion, PAH-specific therapy resulted in significant improvement in both PH and 6MWD.